Extended Data Fig. 10: Tumour clonality and neoantigen quality in biomarker-evaluable patients, and mutated TP53 in a disappearing liver lesion.
From: Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer
(A) Shannon entropy (S) of tumour clones in autogene cevumeran (vaccine) responders and non-responders. (B) Receiver operating curve indicating the ability of neoantigen quality as a continuous variable to classify vaccine neoantigens as an inducer or non-inducer of an IFNγ ELISpot response. Dotted line = all neoantigens included in individualized mRNA vaccines. (C) Digital droplet PCR showing number of wild-type (WT) TP53, or R175H mutated TP53 droplets in liver lesion from patient 29 (Fig. 4), with positive and negative (gDNA) controls. n = individual patients (A) or neoantigens (B). P values by two-tailed Mann-Whitney test.
